Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy

NCT00461136 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00461136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00461136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy
Lead sponsor
Novartis
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2005
Completion date
November 30, 2006
Enrollment
18
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes type 2